Amgen (AMGN): FY26 Q3 earnings call, Nov 3, 2026
On its Nov 3, 2026 earnings call (FY26 Q3), Amgen said 6 of the 14 words Kalshi listed; Parrot’s count agreed with all 14 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
14 words · 6 settled yes · our count agreed on 14 of 14- Kalshi: company speakers + operator
Kalshi
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Dazodalibep | Yes | 9 | 9 | ✓ | 70%transcripts from the transcript model | – |
| Eosinophilic | Yes | 6 | 6 | ✓ | 65%transcripts from the transcript model | – |
| ESMO | Yes | 5 | 7 | ✓ | 31%transcripts from the transcript model | – |
| Imfinzi / Durvalumab | Yes | 5 | 5 | ✓ | 20%transcripts from the transcript model | – |
| GLP-1 / GLP | Yes | 4 | 5 | ✓ | 78%transcripts from the transcript model | – |
| Medicare | Yes | 1 | 2 | ✓ | 39%transcripts from the transcript model | – |
| Oral 3+ times | No | 1 | 1 | ✓ | 55%transcripts from the transcript model | – |
| Artificial Intelligence 3+ times | No | 1 | 1 | ✓ | 28%transcripts from the transcript model | – |
| Tavneos | No | 0 | 0 | ✓ | 68%transcripts from the transcript model | – |
| Acquisition | No | 0 | 0 | ✓ | 53%transcripts from the transcript model | – |
| Prolia 2+ times | No | 0 | 0 | ✓ | 35%transcripts from the transcript model | – |
| Litigation | No | 0 | 0 | ✓ | 31%transcripts from the transcript model | – |
| Patent 2+ times | No | 0 | 0 | ✓ | 29%transcripts from the transcript model | – |
| Buyback / Buy Back | No | 0 | 0 | ✓ | 16%transcripts from the transcript model | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Nov 3, 2026 23:56 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
0 matches for “Imfinzi / Durvalumab”.
Where the listed words were said
…cornerstone therapy, TEZSPIRE in eosinophilic esophagitis, an area with significant unmet need, and dazodalibep in Sjögren's disease, where no approved disease-modifying therapies currently exist.
…in the need for surgery. More recently, positive phase III results in eosinophilic esophagitis, or EoE, demonstrated meaningful improvements in key measures of disease activity…
…first-line maintenance study of IMDELLTRA with anti-PD-L1 therapy was also presented at ESMO, remarkably featuring a median overall survival of 37 months. These results are…
…phase III results from the DeLLphi-305 study evaluating IMDELLTRA in combination with IMFINZI in first-line maintenance treatment. I was at the European Society for Medical…
…start and stay on MariTide, and how others can switch from other GLP-1-based medicines and stay on MariTide. Our goal is to make long-term treatment…
…we're interested in seeing what other government access programs evolve to over time. I think it's good that we've got Medicare access in this category.
Agents: this page as TSV at /api/v1/appearances/amgen:2026-11-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-11-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP